Carl Gordon at Orbimed New Horizons: Filed Board Seats

Where do filings name Carl Gordon on the board?

32 filed

Board seats filed for Carl Gordon, sortable by column.

Star Therapeutics	Biotech & pharma	September 2025	Caduceus Capital, Orbimed Asia Partners, Orbimed Partners, Sofinnova Venture Partners
Lomond Therapeutics Holdings	Biotech & pharma	November 2024	Caduceus Capital, Orbimed Asia Partners, Orbimed Partners
Belenos Biosciences	Biotech & pharma	July 2024	Caduceus Capital, Orbimed Asia Partners, Orbimed Partners
ArriVent Biopharma	Biotech & pharma	December 2022	Caduceus Capital, Orbimed Asia Partners, Orbimed Partners, Sofinnova Venture Partners
MBX Biosciences	Biotech & pharma	November 2022	Caduceus Capital, New Enterprise Associates, Orbimed Asia Partners, Orbimed Partners
Avenzo Therapeutics	Biotech & pharma	September 2022	Caduceus Capital, Orbimed Asia Partners, Orbimed Partners
Alterome Therapeutics	Biotech & pharma	December 2021	Caduceus Capital, Orbimed Asia Partners, Orbimed Partners
Garuda Therapeutics	Biotech & pharma	September 2021	Caduceus Capital, Orbimed Asia Partners, Orbimed Partners
Odyssey Therapeutics	Biotech & pharma	August 2021	Abingworth Bioventures, Caduceus Capital, Orbimed Asia Partners, Orbimed Partners
Scribe Therapeutics	Biotech & pharma	March 2021	Caduceus Capital, Orbimed Asia Partners, Orbimed Partners
BlossomHill Therapeutics	Biotech & pharma	March 2021	Caduceus Capital, Orbimed Asia Partners, Orbimed Partners, Vivo Capital
ADARx Pharmaceuticals	Biotech & pharma	July 2020	Caduceus Capital, Orbimed Asia Partners, Orbimed Partners, Vivo Capital
Compass Therapeutics	Biotech & pharma	June 2020	Caduceus Capital, Orbimed Asia Partners, Orbimed Partners
Keros Therapeutics	Biotech & pharma	March 2020	Caduceus Capital, Orbimed Asia Partners, Orbimed Partners
Kinnate Biopharma	Biotech & pharma	December 2019	Caduceus Capital, Orbimed Asia Partners, Orbimed Partners
Kumquat Biosciences	Biotech & pharma	July 2019	Caduceus Capital, Orbimed Asia Partners, Orbimed Partners
SpringWorks Therapeutics	Biotech & pharma	March 2019	Caduceus Capital, Orbimed Asia Partners, Orbimed Partners, Passage BIO Inc
TP Therapeutics	Biotech & pharma	October 2018	Caduceus Capital, Orbimed Asia Partners, Orbimed Partners, Vivo Capital
Theseus Pharmaceuticals	Biotech & pharma	June 2018	Caduceus Capital, Orbimed Asia Partners, Orbimed Partners
Prevail Therapeutics	Biotech & pharma	March 2018	Caduceus Capital, Orbimed Asia Partners, Orbimed Partners
SpringWorks Therapeutics	Biotech & pharma	August 2017	Caduceus Capital, Orbimed Asia Partners, Orbimed Partners
Gemini Therapeutics	Biotech & pharma	April 2016	Atlas Venture, Caduceus Capital, Lightstone Ventures, Orbimed Asia Partners, Orbimed Partners
Alector	Biotech & pharma	September 2015	Caduceus Capital, Orbimed Asia Partners, Orbimed Partners
Intellia Therapeutics	Biotech & pharma	August 2015	Atlas Venture, Caduceus Capital, Orbimed Asia Partners, Orbimed Partners
Adicet Bio	Biotech & pharma	August 2015	Caduceus Capital, Orbimed Asia Partners, Orbimed Partners
Compass Therapeutics	Biotech & pharma	June 2015	Caduceus Capital, Orbimed Asia Partners, Orbimed Partners
SELECTA BIOSCIENCES	Biotech & pharma	April 2014	Caduceus Capital, Orbimed Asia Partners, Orbimed Partners, Polaris Partners
IGENICA	Biotech & pharma	January 2014	Caduceus Capital, Orbimed Asia Partners, Orbimed Partners, The Column Group
Arsanis	Biotech & pharma	July 2013	Caduceus Capital, Orbimed Asia Partners, Orbimed Partners, Polaris Partners, SV Life Sciences
Singulex	Biotech & pharma	February 2012	Caduceus Capital, Orbimed Asia Partners, Orbimed Partners
Aragon Pharmaceuticals	Biotech & pharma	February 2012	Caduceus Capital, Orbimed Asia Partners, Orbimed Partners, The Column Group
ACCELERON PHARMA	Healthcare services	December 2011	Caduceus Capital, Lightstone Ventures, Orbimed Asia Partners, Orbimed Partners, Polaris Partners

The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.

Carl Gordon

Where do filings name Carl Gordon on the board?

What sectors do their boards fall in?